Loading clinical trials...
Loading clinical trials...
An Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months.
Conditions
Interventions
Quadrivalent influenza vaccine(0.25ml)
Quadrivalent influenza vaccine(0.5ml)
+2 more
Locations
4
China
Huaiyin Center for Diseases Control and Prevention
Huai'an, Jiangsu, China
Ganyu District Center for Disease Control and Prevention
Lianyungang, Jiangsu, China
Donghai District Center for Disease Prevention and Control
Lianyungang, Jiangsu, China
Binhai District Center for Disease Control and Prevention
Yancheng, Jiangsu, China
Start Date
August 8, 2022
Primary Completion Date
August 4, 2023
Completion Date
August 4, 2023
Last Updated
May 28, 2024
NCT06602024
NCT05827978
NCT05827068
NCT05333289
NCT04956575
NCT05512494
Lead Sponsor
Sinovac Biotech Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions